This study identified that the association between surgical delay and BCSM risk varies by tumor subtype, with a rapid exponential increase in risk in HR+/HER2− patients and lesser linear increases in patients with HER2 + or HR−/HER2− breast cancer. This evidence concerns the gene ERBB2 and neoplasm.